Allena Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALNAQ research report →
About the company
Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on unearthing, developing, and marketing oral enzyme therapies. These treatments are devised to assist patients in the United States afflicted by uncommon and serious metabolic as well as renal conditions.
- IPO
- 2017
- Employees
- 12
- HQ
- Newton, MA, US
Price Chart
- Market Cap
- $122
- P/E
- -0.07
- P/S
- 0.00
- P/B
- 0.13
- EV/EBITDA
- 0.92
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -160.99%
- ROIC
- -166.72%
- Revenue
- $0 · 0.00%
- Net Income
- $-49,639,000 · -51.90%
- EPS
- $-0.73 · 27.72%
- Op Income
- $-47,649,000
- FCF YoY
- -60.87%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -14.54
- Avg Volume
- 24.85K
Get TickerSpark's AI analysis on ALNAQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALNAQ coverage
Recent articles, reports, and earnings notes.
No research on ALNAQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALNAQ report →Similar companies
Peers in the same neighborhood.